A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation.

Trial Profile

A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Enasidenib (Primary) ; Azacitidine; Cytarabine; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms IDHENTIFY
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 25 Jun 2017 Results assessing differentiation syndrome associated with enasidenib in patients with relapsed/refractory acute myeloid leukaemia using patient data from NCT02577406 and NCT01915498 trials, presented at the 22nd Congress of the European Haematology Association
    • 10 Jun 2017 Biomarkers information updated
    • 26 Apr 2017 Planned End Date changed from 27 Feb 2020 to 27 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top